Repurposing Diflunisal for Familial Amyloid Polyneuropathy: A Randomized Clinical Trial
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
IMPORTANCE: Familial amyloid polyneuropathy, a lethal genetic disease caused by aggregation of variant transthyretin, induces progressive peripheral nerve deficits and disability. Diflunisal, a nonsteroidal anti-inflammatory agent, stabilizes transthyretin tetramers and prevents amyloid fibril formation in vitro. OBJECTIVE: To determine the effect of diflunisal on polyneuropathy progression in patients with familial amyloid polyneuropathy. DESIGN, SETTING, AND PARTICIPANTS: International randomized, double-blind, placebo-controlled study conducted among 130 patients with familial amyloid polyneuropathy exhibiting clinically detectable peripheral or autonomic neuropathy at amyloid centers in Sweden (Umeå), Italy (Pavia), Japan (Matsumoto and Kumamoto), England (London), and the United States (Boston, Massachusetts; New York, New York; and Rochester, Minnesota) from 2006 through 2012. INTERVENTION: Participants were randomly assigned to receive diflunisal, 250 mg (n=64), or placebo (n=66) twice daily for 2 years. MAIN OUTCOMES AND MEASURES: The primary end point, the difference in polyneuropathy progression between treatments, was measured by the Neuropathy Impairment Score plus 7 nerve tests (NIS+7) which ranges from 0 (no neurological deficits) to 270 points (no detectable peripheral nerve function). Secondary outcomes included a quality-of-life questionnaire (36-Item Short-Form Health Survey [SF-36]) and modified body mass index. Because of attrition, we used likelihood-based modeling and multiple imputation analysis of baseline to 2-year data. RESULTS: By multiple imputation, the NIS+7 score increased by 25.0 (95% CI, 18.4-31.6) points in the placebo group and by 8.7 (95% CI, 3.3-14.1) points in the diflunisal group, a difference of 16.3 points (95% CI, 8.1-24.5 points; P < .001). Mean SF-36 physical scores decreased by 4.9 (95% CI, -7.6 to -2.2) points in the placebo group and increased by 1.5 (95% CI, -0.8 to 3.7) points in the diflunisal group (P < .001). Mean SF-36 mental scores declined by 1.1 (95% CI, -4.3 to 2.0) points in the placebo group while increasing by 3.7 (95% CI, 1.0-6.4) points in the diflunisal group (P = .02). By responder analysis, 29.7% of the diflunisal group and 9.4% of the placebo group exhibited neurological stability at 2 years (<2-point increase in NIS+7 score; P = .007). CONCLUSIONS AND RELEVANCE: Among patients with familial amyloid polyneuropathy, the use of diflunisal compared with placebo for 2 years reduced the rate of progression of neurological impairment and preserved quality of life. Although longer-term follow-up studies are needed, these findings suggest benefit of this treatment for familial amyloid polyneuropathy. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00294671.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
(2001) · Statistics for Psychologists · doi:10.4324/9781410605542-11 · Cited by 6,877
The prevention and treatment of missing data in clinical trials
Little, R. J., D'Agostino, R., Cohen, M. L., Dickersin, K., Emerson, S. S., Farrar, J. T., Frangakis, C., Hogan, J. W., Molenberghs, G., Murphy, S. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmsr1203730 · Cited by 1,884
ANDRADE, C. (1952) · Brain · doi:10.1093/brain/75.3.408 · Cited by 1,074
Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial
Coelho, T., Maia, L. F., Martins da Silva, A., Waddington Cruz, M., Planté-Bordeneuve, V., Lozeron, P., Suhr, O. B., Campistol, J. M., Conceição, I. M., Schmidt, H. H.-J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182661eb1 · Cited by 816
Self-citationBlake, C. C. F., Geisow, M. J., Oatley, S. J., Rérat, B., & Rérat, C. (1978) · Journal of Molecular Biology · doi:10.1016/0022-2836(78)90368-6 · Cited by 791
Guideline of transthyretin-related hereditary amyloidosis for clinicians
Ando, Y., Coelho, T., Berk, J. L., Cruz, M. W., Ericzon, B.-G., Ikeda, S.-I., Lewis, W. D., Obici, L., Planté-Bordeneuve, V., Rapezzi, C., et al. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-31 · Cited by 719
Self-citationPartial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro
Colon, W., & Kelly, J. W. (1992) · Biochemistry · doi:10.1021/bi00151a036 · Cited by 573
Self-citationOral Treatment With α-Lipoic Acid Improves Symptomatic Diabetic Polyneuropathy
Ziegler, D., Ametov, A., Barinov, A., Dyck, P. J., Gurieva, I., Low, P. A., Munzel, U., Yakhno, N., Raz, I., Novosadova, M., et al. (2006) · Diabetes Care · doi:10.2337/dc06-1216 · Cited by 562
Self-citationPrevention of Transthyretin Amyloid Disease by Changing Protein Misfolding Energetics
Hammarström, P., Wiseman, R. L., Powers, E. T., & Kelly, J. W. (2003) · Science · doi:10.1126/science.1079589 · Cited by 525
Self-citationPlasma Exchange in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Dyck, P. J., Daube, J., O'Brien, P., Pineda, A., Low, P. A., Windebank, A. J., & Swanson, C. (1986) · New England Journal of Medicine · doi:10.1056/nejm198602203140801 · Cited by 489
Self-citationDyck, P. J., Litchy, W. J., Kratz, K. M., Suarez, G. A., Low, P. A., Pineda, A. A., Windebank, A. J., Karnes, J. L., & O'Brien, P. C. (1994) · Annals of Neurology · doi:10.1002/ana.410360607 · Cited by 471
Self-citationThe molecular biology and clinical features of amyloid neuropathy
Benson, M. D., & Kincaid, J. C. (2007) · Muscle & Nerve · doi:10.1002/mus.20821 · Cited by 447
Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein
Monaco, H., Rizzi, M., & Coda, A. (1995) · Science · doi:10.1126/science.7754382 · Cited by 409
Holmgren, G., Steen, L., Ekstedt, J., Groth, C., Ericzon, B. ‐., Eriksson, S., Andersen, O., Karlberg, I., Nordén, G., Nakazato, M., et al. (1991) · Clinical Genetics · doi:10.1111/j.1399-0004.1991.tb03085.x · Cited by 396
Dyck, P. J., Davies, J. L., Litchy, W. J., & O'Brien, P. C. (1997) · Neurology · doi:10.1212/wnl.49.1.229 · Cited by 382
Self-citationApfel, S. C., Schwartz, S., Adornato, B. T., Freeman, R., Biton, V., Rendell, M., Vinik, A., Giuliani, M., Stevens, J. C., Barbano, R., et al. (2000) · JAMA · doi:10.1001/jama.284.17.2215 · Cited by 368
Self-citationJohnson, S. M., Wiseman, R. L., Sekijima, Y., Green, N. S., Adamski-Werner, S. L., & Kelly, J. W. (2005) · Accounts of Chemical Research · doi:10.1021/ar020073i · Cited by 303
Self-citationPlasma Exchange in Polyneuropathy Associated with Monoclonal Gammopathy of Undetermined Significance
Dyck, P. J., Low, P. A., Windebank, A. J., Jaradeh, S. S., Gosselin, S., Bourque, P., Smith, B. E., Kratz, K. M., Karnes, J. L., Evans, B. A., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199111213252105 · Cited by 301
Self-citationTrans -Suppression of Misfolding in an Amyloid Disease
Hammarström, P., Schneider, F., & Kelly, J. W. (2001) · Science · doi:10.1126/science.1062245 · Cited by 293
Self-citationDyck, P. J., Litchy, W. J., Lehman, K. A., Hokanson, J. L., Low, P. A., & O'Brien, P. C. (1995) · Neurology · doi:10.1212/wnl.45.6.1115 · Cited by 274
Self-citationSekijima, Y., Dendle, M. A., & Kelly, J. W. (2006) · Amyloid · doi:10.1080/13506120600960882 · Cited by 268
Self-citationSUHR, O., DANIELSSON, Å., HOLMGREN, G., & STEEN, L. (1994) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1994.tb01106.x · Cited by 209
Self-citationMiller, S. R., Sekijima, Y., & Kelly, J. W. (2004) · Laboratory Investigation · doi:10.1038/labinvest.3700059 · Cited by 198
Self-citationThe Pathway by Which the Tetrameric Protein Transthyretin Dissociates
Foss, T. R., Wiseman, R. L., & Kelly, J. W. (2005) · Biochemistry · doi:10.1021/bi051608t · Cited by 193
Self-citationOlofsson, B., Backman, C., Karp, K. H., & Suhr, O. B. (2002) · Transplantation · doi:10.1097/00007890-200203150-00015 · Cited by 169
Self-citationSUHR, O. B., HOLMGREN, G., STEEN, L., WIKSTRÖM, L., NORDEN, G., FRIMAN, S., DURAJ, F. F., GROTH, C. G., & ERICZON, B.-G. (1995) · Transplantation · doi:10.1097/00007890-199511000-00009 · Cited by 167
Self-citationProgression of transthyretin amyloid neuropathy after liver transplantation
Liepnieks, J. J., Zhang, L. Q., & Benson, M. D. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ea15d4 · Cited by 158
Dyck, P. J. (1988) · Journal of Sound and Vibration · doi:10.1016/0022-460x(88)90273-8 · Cited by 156
Self-citationA PECULIAR FORM OF PERIPHERAL NEUROPATHY
Andrade, C. (1951) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1951.tb09673.x · Cited by 137
Liver transplantation for familial amyloidotic polyneuropathy: Impact on Swedish patients' survival
Okamoto, S., Wixner, J., Obayashi, K., Ando, Y., Ericzon, B.-G., Friman, S., Uchino, M., & Suhr, O. B. (2009) · Liver Transplantation · doi:10.1002/lt.21817 · Cited by 130
Self-citationSeldin, D. C., Anderson, J. J., Sanchorawala, V., Malek, K. S., Wright, D. G., Quillen, K., Finn, K. T., Berk, J. L., Dember, L. M., Falk, R. H., et al. (2004) · Blood · doi:10.1182/blood-2004-01-0089 · Cited by 115
Self-citationTashima, K., Ando, Y., Terazaki, H., Yoshimatsu, S., Suhr, O. B., Obayashi, K., Yamashita, T., Ando, E., Uchino, M., & Ando, M. (1999) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(99)00231-2 · Cited by 70
Self-citationCoelho, T., Chorão, R., Sousa, A., Alves, I. L., Torres, M. F., & Saraiva, M. J. (1996) · Neuromuscular Disorders · doi:10.1016/0960-8966(96)88826-2 · Cited by 61
Effect of Blood Glucose Control on Peripheral Nerve Function in Diabetic Patients
Service, F. J., Daube, J. R., Zimmerman, B. R., O’Brien, P. C., Swanson, C., Brennan, M., & Dyck, P. J. B. (1983) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(25)18769-7 · Cited by 40
Self-citationDyck, P. J., Overland, C. J., Low, P. A., Litchy, W. J., Davies, J. L., Dyck, P. J., Carter, R. E., Melton, L. J., Andersen, H., Albers, J. W., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1481 · Cited by 39
Self-citationAutonomic neuropathy, II: Specific peripheral neuropathies
McDougall, A., & McLeod, J. G. (1996) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(95)00356-7 · Cited by 36
Cited by
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Self-citation2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107454 · Cited by 1,801
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., Planté-Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,452
Self-citation
Metadata
- Authors
- Berk, J. L., Suhr, O. B., Obici, L., Sekijima, Y., Zeldenrust, S. R., Yamashita, T., Heneghan, M. A., Gorevic, P. D., Litchy, W. J., Wiesman, J. F., Nordh, E., Corato, M., Lozza, A., Cortese, A., Robinson-Papp, J., Colton, T., Rybin, D. V., Bisbee, A. B., Ando, Y., Ikeda, S.-I., Seldin, D. C., Merlini, G., Skinner, M., Kelly, J. W., & Dyck, P. J.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2013-12-25
- Volume
- 310
- Issue
- 24
- Pages
- 2658
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2148373528
- Cited by
- 708
- References
- 37
- FWCI
- 17.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.